Atovaquone/proguanil: the need for family protection.
An increasing number of families, including children and the elderly, are seeking more adventurous travel in exotic parts of the world. Holiday destinations now include once-remote regions such as subSaharan Africa and New Guinea. This increase in visits to tropical and subtropical regions, combined with widespread chloroquine-resistant malaria, now places millions of Western travelers at risk of infection annually. At least 30,000 travelers from industrialized countries are reported to contract malaria each year and approximately 1 in 100 travelers who acquire Plasmodium falciparum malaria will die.
Kain
Kevin C
KC
Center for Travel and Tropical Medicine, Toronto General Hospital and University of Toronto, Toronto, Canada.
D000328:Adult; D017954:Africa South of the Sahara; D000368:Aged; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D053626:Atovaquone; D002648:Child; D004338:Drug Combinations; D004351:Drug Resistance; D005190:Family; D006801:Humans; D008288:Malaria / Q000401:mortality / Q000517:prevention & control*; D009285:Naphthoquinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009512:New Guinea; D002727:Proguanil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014195:Travel; D014481:United States / Q000453:epidemiology
D000962:Antimalarials; D004338:Drug Combinations; D009285:Naphthoquinones; C109496:atovaquone, proguanil drug combination; D002727:Proguanil; D053626:Atovaquone